📣 VC round data is live. Check it out!
- Public Comps
- Prelude Therapeutics
Prelude Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Prelude Therapeutics and similar public comparables like IMBiologics, Santhera Pharma, Zentalis Pharma, Oryzon Genomics and more.
Prelude Therapeutics Overview
About Prelude Therapeutics
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Founded
2016
HQ

Employees
131
Website
Financials (LTM)
EV
$216M
Valuation Multiples
Start free trialPrelude Therapeutics Financials
Prelude Therapeutics reported last 12-month revenue of $19M and negative EBITDA of ($109M).
In the same LTM period, Prelude Therapeutics generated ($109M) in EBITDA losses and had net loss of ($83M).
Revenue (LTM)
Prelude Therapeutics P&L
In the most recent fiscal year, Prelude Therapeutics reported revenue of $12M and EBITDA of ($103M).
Prelude Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of (847%) and net margin of (820%).
Financial data powered by Morningstar, Inc.
Prelude Therapeutics Stock Performance
Prelude Therapeutics has current market cap of $280M, and enterprise value of $216M.
Market Cap Evolution
Prelude Therapeutics' stock price is $3.51.
Prelude Therapeutics share price decreased by 10.2% in the last 30 days, and increased by 333.7% in the last year.
Prelude Therapeutics has an EPS (earnings per share) of $-1.25.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $216M | $280M | -8.1% | -10.2% | 2.7% | 333.7% | $-1.25 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPrelude Therapeutics Valuation Multiples
Prelude Therapeutics trades at 11.3x EV/Revenue multiple, and (2.0x) EV/EBITDA.
EV / Revenue (LTM)
Prelude Therapeutics Financial Valuation Multiples
As of June 4, 2026, Prelude Therapeutics has market cap of $280M and EV of $216M.
Prelude Therapeutics has a P/E ratio of (3.4x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Prelude Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Prelude Therapeutics Margins & Growth Rates
Prelude Therapeutics grew revenue by 134% and EBITDA by 11% in the last fiscal year.
In the most recent fiscal year, Prelude Therapeutics reported EBITDA margin of (847%) and net margin of (820%).
Prelude Therapeutics Margins
Prelude Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Prelude Therapeutics Operational KPIs
Prelude Therapeutics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.9M for the same period.
Prelude Therapeutics' Rule of 40 is (268%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Prelude Therapeutics' Rule of X is (66%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Prelude Therapeutics Competitors
Prelude Therapeutics competitors include IMBiologics, Santhera Pharma, Zentalis Pharma, Oryzon Genomics, Immuneering, Panacea Biotec, Eledon Pharmaceuticals, Organogenesis, Surrozen and SAB Bio.
Most Prelude Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | 27.6x | - | - | |||
| 3.2x | 2.9x | (7.8x) | (11.9x) | |||
| - | - | (0.7x) | (0.7x) | |||
| - | 78.6x | (44.4x) | (25.5x) | |||
| - | - | (2.1x) | - | |||
| 3.9x | - | 79.5x | - | |||
| - | - | (2.0x) | - | |||
| 0.7x | 0.9x | 4.1x | 17.7x | |||
This data is available for Pro users. Sign up to see all Prelude Therapeutics competitors and their valuation data. Start Free Trial | ||||||
Prelude Therapeutics VC Funding History
Before going public, Prelude Therapeutics raised $122M in total equity funding, across 3 rounds.
Prelude Therapeutics Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Prelude Therapeutics
| When was Prelude Therapeutics founded? | Prelude Therapeutics was founded in 2016. |
| Where is Prelude Therapeutics headquartered? | Prelude Therapeutics is headquartered in United States. |
| How many employees does Prelude Therapeutics have? | As of today, Prelude Therapeutics has over 131 employees. |
| Who is the CEO of Prelude Therapeutics? | Prelude Therapeutics' CEO is Krishna Vaddi. |
| Is Prelude Therapeutics publicly listed? | Yes, Prelude Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Prelude Therapeutics? | Prelude Therapeutics trades under PRLD ticker. |
| When did Prelude Therapeutics go public? | Prelude Therapeutics went public in 2020. |
| Who are competitors of Prelude Therapeutics? | Prelude Therapeutics main competitors include IMBiologics, Santhera Pharma, Zentalis Pharma, Oryzon Genomics, Immuneering, Panacea Biotec, Eledon Pharmaceuticals, Organogenesis, Surrozen, SAB Bio. |
| What is the current market cap of Prelude Therapeutics? | Prelude Therapeutics' current market cap is $280M. |
| What is the current revenue of Prelude Therapeutics? | Prelude Therapeutics' last 12 months revenue is $19M. |
| What is the current revenue growth of Prelude Therapeutics? | Prelude Therapeutics revenue growth (NTM/LTM) is 105%. |
| What is the current EV/Revenue multiple of Prelude Therapeutics? | Current revenue multiple of Prelude Therapeutics is 11.3x. |
| Is Prelude Therapeutics profitable? | No, Prelude Therapeutics is not profitable. |
| What is the current EBITDA of Prelude Therapeutics? | Prelude Therapeutics has negative EBITDA and is not profitable. |
| What is Prelude Therapeutics' EBITDA margin? | Prelude Therapeutics' last 12 months EBITDA margin is (572%). |
| What is the current EV/EBITDA multiple of Prelude Therapeutics? | Current EBITDA multiple of Prelude Therapeutics is (2.0x). |
| What is the current FCF of Prelude Therapeutics? | Prelude Therapeutics' last 12 months FCF is $58M. |
| What is Prelude Therapeutics' FCF margin? | Prelude Therapeutics' last 12 months FCF margin is 307%. |
| What is the current EV/FCF multiple of Prelude Therapeutics? | Current FCF multiple of Prelude Therapeutics is 3.7x. |
| How many companies Prelude Therapeutics has acquired to date? | Prelude Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Prelude Therapeutics has invested to date? | Prelude Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Prelude Therapeutics
Lists including Prelude Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.